All News
Filter News
Found 91 articles
-
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
2/28/2022
Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
-
Three genome editing companies, Intellia Therapeutics, Editas Medicine and uniQure, are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.
-
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
2/24/2022
Intellia Therapeutics, Inc., a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the fourth quarter and year ended December 31, 2021.
-
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
2/17/2022
Intellia Therapeutics, Inc. today announced that it will be hosting two virtual investor events in February.
-
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022
1/6/2022
Intellia Therapeutics, Inc. today outlined its expected milestones and the following strategic priorities for 2022.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
Clinical Catch-Up: November 22-26
11/29/2021
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look. -
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
11/22/2021
Intellia Therapeutics, Inc. announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved a protocol amendment for the Company’s ongoing Phase 1 study of NTLA-2001 to include patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
-
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
11/4/2021
Intellia Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021, and recent operational highlights.
-
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
-
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
10/21/2021
Intellia Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis.
-
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
10/6/2021
Intellia Therapeutics, Inc. today announced the authorization of its Clinical Trial Application (CTA) by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to initiate a Phase 1/2 study evaluating NTLA-2002 for the treatment of adults with hereditary angioedema (HAE).
-
NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML).
-
On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.
-
Regeneron Reports Second Quarter 2021 Financial and Operating Results
8/5/2021
Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2021 and provided a business update.
-
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
8/5/2021
Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported financial results for the second quarter ended June 30, 2021, and recent operational highlights.
-
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
-
This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures.
-
Money on the Move: June 30 – July 6
7/7/2021
The long weekend didn't slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. -
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.